AXL inhibitor SGI-7079 suppresses the growth of retinoblastoma via PI3K/AKT/mTOR pathway
Experimental Eye Research · 2026-07 · 268 · 110993
DOI: 10.1016/j.exer.2026.110993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2026-07. Verfasst von Tingting Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and …. Hauptthemen laut MEDLINE: Retinoblastoma, TOR Serine-Threonine Kinases, Retinal Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Major Projects of Guangdong Education Department for Foundation Research and Applied Research, National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
Among children, retinoblastoma (RB) is the leading primary ocular tumor, and AXL emerges as a significant player in tumors. Our research showed AXL's expression was elevated in clinical retinoblastoma tumors relative to normal retinas. This upregulation was further validated through analysis of the GEO database. In vitro, SGI-7079 (AXL inhibitor) reduced RB cell line growth in a manner that depended on time and concentration, resulting in G2/M phase accumulation and apoptosis, and suppressed the expression of the PI3K/AKT/mTOR pathway. In vivo, SGI-7079 suppressed xenograft tumor growth. In summary, the research indicates that SGI-7079 might become a therapeutic strategy for RB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, Guangdong, China.
- Department of Ophthalmology, The Second Hospital of Yibin, Yibin, Sichuan, China.
- Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, China.
- Department of Ophthalmology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Department of Ophthalmology, Jiangxi Provincial People's Hospital & the First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China. Electronic address: 1322391287@qq.com.
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, Guangdong, China. Electronic address: huang…
Förderung
- Major Projects of Guangdong Education Department for Foundation Research and Applied Research
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- State Key Laboratory of Ophthalmology
Zitieren
APA
Chen, T., Lu, Y., Yao, C., Chen, Y., Wu, W., Zhang, Y., & Huang, G. (2026). AXL inhibitor SGI-7079 suppresses the growth of retinoblastoma via PI3K/AKT/mTOR pathway. Experimental Eye Research, 268, 110993. https://doi.org/10.1016/j.exer.2026.110993
Vancouver
Chen T, Lu Y, Yao C, Chen Y, Wu W, Zhang Y, et al. AXL inhibitor SGI-7079 suppresses the growth of retinoblastoma via PI3K/AKT/mTOR pathway. Experimental Eye Research. 2026;268:110993. doi:10.1016/j.exer.2026.110993
BibTeX
@article{Chen2026,
author = {Chen, Tingting and Lu, Yongan and Yao, Chunyue and Chen, Yijia and Wu, Weiqi and Zhang, Yanyan and Huang, Guofu},
title = {AXL inhibitor SGI-7079 suppresses the growth of retinoblastoma via PI3K/AKT/mTOR pathway},
journal = {Experimental Eye Research},
year = {2026},
volume = {268},
pages = {110993},
doi = {10.1016/j.exer.2026.110993}
}
EUVIMED